Seer appoints Scott Thomas as Chief Commercial Officer effective March 21, 2022

Seer, Inc.

Scott Thomas appointed CCO, effective March 21, 2022; previously SVP at Singular Genomics and various roles at Illumina.
Base salary of $395,000; target annual bonus of 40% of base salary, prorated for 2022.
Sign-on bonus of $50,000 (grossed up) subject to repayment if employment ends before two-year anniversary.
Initial equity grant recommended: stock option for 110,000 shares and RSU for 26,000 shares with time-based vesting.
Eligible for Key Executive Change in Control and Severance Plan with severance benefits for qualifying termination.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Scott Thomas

Chief Commercial Officer

SEER · Seer, Inc.

Effective: 2022-03-21
Filed: March 18, 2022, 7:59 PM ET

On March 16, 2022, Seer, Inc., (the “Company”) announced that Scott Thomas has been appointed to the role of Chief Commercial Officer , effective upon commencement of his employment with the Company on March 21, 2022 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Thomas was appointed as Chief Commercial Officer at Seer, Inc..

Action: appointed
Role: Chief Commercial Officer

Exact text from the filing

On March 16, 2022, Seer, Inc., (the “Company”) announced that Scott Thomas has been appointed to the role of Chief Commercial Officer , effective upon commencement of his employment with the Company on March 21, 2022 (the “Effective Date”).

View on SEC.gov

Seer, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-006720

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.